Burkina Faso recorded 7,329,278 malaria cases in 2025, down from 10,805,020 in 2024 — a drop of 32 percent. Deaths fell from 3,523 to 1,979, a 44 percent decline. Health Minister Robert Kargougou put those national counts on the record at a February 2026 briefing; Gavi published them on 24 April 2026.
On 24 August 2026, WHO Director-General Tedros Adhanom Ghebreyesus cited the same movement in opening remarks to the 76th session of the Regional Committee for Africa: the Big Catch-up reached more than 18 million children who had missed vaccines, WHO had supported malaria-vaccine rollout in 25 countries, and “in Burkina Faso, cases have already fallen by nearly a third.”
This is not elimination. It is not a vaccine-only story. Seasonal chemoprevention, insecticide-treated nets, indoor spraying, larval control and treatment ran in parallel. And Africa still carries most of the global burden. WHO’s malaria-vaccine Q&A, dated 4 February 2026, puts 2024 at an estimated 282 million cases and 610,000 deaths worldwide, with the African Region accounting for 94 percent of cases and 95 percent of deaths.
Why it matters
Malaria still kills children at a scale that makes a one-year national drop news. WHO estimates about 438,000 African children died from the disease in 2024. Malaria Consortium, writing on 15 July 2026, notes that Burkina Faso remains among the ten countries with the highest case and death counts. If a package that now includes a childhood malaria vaccine can move a high-burden country’s official register by a third in a single year, that is a public-health print, not a trial abstract.
The same speech that named the one-third drop also named the constraint. Tedros told ministers that HIV, TB, malaria and maternal programmes were among those hit hardest by last year’s financing cuts. Supply of the two WHO-recommended shots — RTS,S/AS01 and R21/Matrix-M — is no longer the bottleneck WHO describes. Funding is. The Burkina Faso numbers are the argument for paying for the package. They are not a claim that the rest of the continent has already followed.
A death-rate file is a different instrument from a malaria register, but both are how public-health progress gets measured rather than asserted. The United States just printed a record-low age-adjusted death rate in provisional 2025 data; that story is The US death rate just hit a recorded low. Burkina Faso’s 2025 malaria file is this week’s counterpart: a named count, a named year, a named minister.
The 2024–2025 print
Gavi, citing the February briefing, published the national totals:
| 2024 | 2025 | Change | |
|---|---|---|---|
| Recorded malaria cases | 10,805,020 | 7,329,278 | −32% |
| Recorded malaria deaths | 3,523 | 1,979 | −44% |
Under-five numbers diverge by source, so both stay on the page. Gavi says cases in children under five declined 39 percent and mortality fell by more than 40 percent. Malaria Consortium, using national data, says under-five deaths dropped from over 2,200 in 2024 to around 1,300 in 2025 — almost 60 percent. Those are not the same statistic. We are not picking the juicier figure.
Facility-level counts move in the same direction. At Cissin 17, a health centre in Ouagadougou, head nurse Boubakaré Sawadogo told Gavi that confirmed malaria in children under five fell from 944 in 2024 to 538 in 2025. Confirmed cases in pregnant women fell from 548 to 231. Clarisse Toé, a paediatric ward supervisor at the Pissy Medical Centre, said the 2025 rainy season did not overwhelm the unit the way staff usually expect.
How they did it
Burkina Faso introduced RTS,S/AS01 in February 2024 in 27 health districts. In August 2025 it scaled malaria vaccination across all districts with R21, Dr Pierre Kayende, Malaria Consortium’s country director, said. WHO’s 2024–2025 Burkina Faso biennial report puts that scale-up at all 70 health districts. In Burkina Faso the shot is four doses, scheduled at 5, 6, 7 and 15 months.
The vaccine arrived on top of a stack, not instead of one. Consortium lists seasonal malaria chemoprevention; free long-lasting insecticidal nets — about 15 million distributed in 2025, a figure WHO’s biennial report also uses; indoor residual spraying in nine health districts; larval control in twelve; and community distributors destroying more than 2.1 million mosquito breeding sites. WHO’s biennial adds that more than 5 million children received seasonal chemoprevention. Gavi’s reporting from Cissin 17 names the same mix: nets, spraying, rapid tests, treatment, free medicines for some groups, plus the new vaccine. Sawadogo: “With all these measures combined, we are seeing a real impact on reducing cases. The vaccine has further strengthened the fight against the disease.”
That is also WHO’s position. Both RTS,S and R21 are prequalified. In phase 3 trials both cut malaria cases by more than 50 percent in the first year after vaccination; a fourth dose prolongs protection; both cut cases by about 75 percent when given seasonally where chemoprevention is already provided. An independent evaluation of the first-country pilots in Ghana, Kenya and Malawi — published in The Lancet and summarised by WHO on 8 May 2026 — found that among children eligible for the vaccine, an estimated 1 in 8 child deaths were averted over four years, a 13 percent drop in mortality. More than 10 million children a year are now targeted across the 25 countries.
Gavi finances Burkina Faso’s malaria-vaccine programme; UNICEF supports supply, the cold chain, training and mobilisation; WHO provides technical guidance. Other partners named in the April Gavi dispatch include Jhpiego and USAID.
What this is not
Burkina Faso has not eliminated malaria. Sidzabda Kompaoré, Permanent Secretary for Malaria Elimination, told Gavi the 2025 results are encouraging and that malaria remains a major public-health challenge. The stated national ambition is elimination by 2030. Tedros, in the same 24 August speech, said about 70 percent of maternal deaths and almost half of under-five deaths globally still occur in Africa. WHO’s Q&A is blunt: highest impact comes when vaccines sit inside a comprehensive control strategy.
The 2025 Burkina Faso counts are national reported cases and deaths, not a randomised trial of the vaccine alone. Facility registers can move with testing, care-seeking and reporting. The direction is consistent across the ministry briefing, Gavi, Malaria Consortium and Tedros. Attribution to a single tool is not.
What to watch
- The 2026 transmission season. One good year is a print, not a trend. The next rainy-season file is the test.
- Under-five deaths, source by source. Gavi’s “more than 40 percent” and Consortium’s “almost 60 percent” need a single official under-five table before anyone treats 60 percent as the national figure.
- Coverage versus target. WHO says most of the 25 countries are still below national scale because of funding, even though supply can meet demand. Burkina Faso’s nationwide R21 step in August 2025 is the exception to watch, not the default.
- Financing. Tedros told the Regional Committee that last year’s cuts hit malaria programmes hard. Dr Kate O’Brien, WHO’s immunisation director, said on 8 May that demand is high and supply is sufficient — “more financing is needed so that countries can purchase enough vaccine, along with other malaria prevention tools.”
- The 2030 elimination date. Kayende said the 2025 drop puts Burkina Faso “on the right track.” That is a programme goal, not a forecast.
Sources
- Tedros Adhanom Ghebreyesus, opening remarks, 76th WHO Regional Committee for Africa, 24 August 2026 — https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-76th-session-of-the-regional-committee-for-africa---24-august-2026
- Abdel Aziz Nabaloum, “Two years after the introduction of the malaria vaccine, Burkina Faso celebrates its impact,” Gavi VaccinesWork, 24 April 2026 — https://www.gavi.org/vaccineswork/two-years-after-introduction-malaria-vaccine-burkina-faso-celebrates-its-impact
- Malaria Consortium, “Burkina Faso records plummeting malaria prevalence,” 15 July 2026 — https://www.malariaconsortium.org/news/burkina-faso-records-plummeting-malaria-prevalence
- WHO, “Malaria vaccines (RTS,S and R21),” Q&A, 4 February 2026 — https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
- WHO, “New evidence confirms malaria vaccine saves child lives and will have high impact in wider rollout,” 8 May 2026 — https://www.who.int/news/item/08-05-2026-new-evidence-confirms-malaria-vaccine-saves-child-lives-and-will-have-high-impact-in-wider-rollout
- WHO Regional Office for Africa, Burkina Faso biennial report 2024–2025 — https://www.afro.who.int/countries/burkina-faso/publication/who-biennial-report-2024-2025-burkina-faso-significant-progress-health-system-resilience-and-access
